What are the mid-term results and costs of coronary artery bypass vs drug-eluting stents for unprotected left main coronary artery disease?
In a study conducted by Shimizu T, Ohno T, Ando J, et al. in 2010, they reported mid-term results and costs of coronary artery bypass (CABG) vs drug-eluting stents (DES) for unprotected left main coronary artery disease. The study found that CABG was preferred over DES in terms of long-term clinical outcomes, with lower overall costs from the perspective of the healthcare system. Moreover, CABG was associated with a lower risk of all-cause mortality, repeat revascularization, and major adverse cardiac events. The study concluded that CABG was a more cost-effective option for treating unprotected left main coronary artery disease compared to DES.